The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | MCL trials to watch out for at ASH 2019
Simon Rule, MD, Plymouth University, Plymouth, UK, gives his insight into the mantle cell lymphoma (MCL) trials to watch out for at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition. Prof. Rule highlights the ZUMA-2 study (NCT02601313), and the use of MRD status for treatment decision-making. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
